The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Inflammatory bowel disease and risk of prostate cancer: A matched-cohort analysis.
 
Adam Weiner
No Relationships to Disclose
 
Jacob A Burns
No Relationships to Disclose
 
William J Catalona
No Relationships to Disclose
 
Eric Li
No Relationships to Disclose
 
Edward M. Schaeffer
Consulting or Advisory Role - Abbvie; OPKO Diagnostics
 
Stephen Hanauer
No Relationships to Disclose
 
Scott Strong
No Relationships to Disclose
 
James Burns
No Relationships to Disclose
 
Maha H. A. Hussain
Honoraria - Genzyme; Onclive; Sanofi
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - AstraZeneca (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Sanofi
 
Shilajit Kundu
No Relationships to Disclose